Cargando…

Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma

Mantle cell lymphoma (MCL) is a rare, incurable hematological malignancy with a heterogeneous presentation and clinical course. A wide variety of chemotherapy-based regimens are currently used in patients who are untreated. Over the last several years, several targeted or small-molecule therapies ha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Phillips, Tycel J., Bond, David, Takiar, Radihka, Kump, Karson, Kandarpa, Malalthi, Boonstra, Philip, Mayer, Tera Lynn, Nachar, Victoria, Wilcox, Ryan A., Carty, Shannon A., Karimi, Yasmin H., Nikolovska-Coleska, Zaneta, Kaminski, Mark S., Herrera, Alex F., Maddocks, Kami, Popplewell, Leslie, Danilov, Alexey V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2023
Materias:	Clinical Trials and Observations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425679/ https://www.ncbi.nlm.nih.gov/pubmed/37013954 http://dx.doi.org/10.1182/bloodadvances.2023009992

Ejemplares similares

Discovery of Mcl-1 inhibitors from integrated high throughput and virtual screening
por: Mady, Ahmed S. A., et al.
Publicado: (2018)

Evaluating Acalabrutinib In The Treatment Of Mantle Cell Lymphoma: Design, Development, And Place In Therapy
por: Girard, Jennifer, et al.
Publicado: (2019)

Machine learning approaches and databases for prediction of drug–target interaction: a survey paper
por: Bagherian, Maryam, et al.
Publicado: (2020)

Erratum to: Machine learning approaches and databases for prediction of drug–target interaction: a survey paper
por: Bagherian, Maryam, et al.
Publicado: (2020)

Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004)
por: Wang, Michael, et al.
Publicado: (2017)

Optimization and validation of mitochondria-based functional assay as a useful tool to identify BH3-like molecules selectively targeting anti-apoptotic Bcl-2 proteins
por: Long, Jianting, et al.
Publicado: (2013)

Clinical Treatment Guidelines for Tafasitamab plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
por: Nedved, Adrienne, et al.
Publicado: (2023)

Durable responses with ALK inhibitors for primary refractory anaplastic lymphoma Kinase-positive large B-cell lymphoma
por: Takiar, Radhika, et al.
Publicado: (2023)

Relapsed Mantle Cell Lymphoma: Current Management, Recent Progress, and Future Directions
por: Bond, David A, et al.
Publicado: (2021)

Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma
por: Portell, Craig A., et al.
Publicado: (2022)

P1259: CHARACTERIZATION OF VENETOCLAX RESISTANCE IN CELL MODELS OF MANTLE CELL LYMPHOMA
por: Granau, A., et al.
Publicado: (2022)

A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma
por: Sawalha, Yazeed, et al.
Publicado: (2023)

Therapeutic Activity of Lenalidomide in Mantle Cell Lymphoma and Indolent Non-Hodgkin's Lymphomas
por: Gunnellini, Marco, et al.
Publicado: (2012)

The WD40 domain of FBXW7 is a poly(ADP-ribose)-binding domain that mediates the early DNA damage response
por: Zhang, Qiang, et al.
Publicado: (2019)

Inhibition of cyclin‐dependent kinase 9 synergistically enhances venetoclax activity in mantle cell lymphoma
por: Zhao, Xiaoxian, et al.
Publicado: (2020)

Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma
por: Thus, Yvonne J., et al.
Publicado: (2022)

Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma
por: Wilson, Wyndham H., et al.
Publicado: (2021)

Nine-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma
por: Yamshon, Samuel, et al.
Publicado: (2023)

Refractory Autoimmune Cytopenias Treated With Venetoclax
por: Gordon, Max J., et al.
Publicado: (2019)

Defining specificity and on-target activity of BH3-mimetics using engineered B-ALL cell lines
por: Koss, Brian, et al.
Publicado: (2016)

P1246: DIFFERENTIAL ROLE OF MICROENVIRONMENT AND STROMAL-CELL INDUCED VENETOCLAX RESISTANCE IN MANTLE CELL LYMPHOMA
por: Andersen, P., et al.
Publicado: (2022)

Inhibition of casein kinase 2 sensitizes mantle cell lymphoma to venetoclax through MCL-1 downregulation
por: Thus, Yvonne J., et al.
Publicado: (2022)

3-Substituted-N-(4-Hydroxynaphthalen-1-yl)arylsulfonamides as a Novel Class of Selective Mcl-1 Inhibitors: Structure-Based Design, Synthesis, SAR, and Biological Evaluation
por: Abulwerdi, Fardokht A., et al.
Publicado: (2014)

Elucidating the Importance of DOT1L Recruitment in MLL-AF9 Leukemia and Hematopoiesis
por: Grigsby, Sierrah M., et al.
Publicado: (2021)

Combination of lenalidomide with vitamin D3 induces apoptosis in mantle cell lymphoma via demethylation of BIK
por: Brosseau, C, et al.
Publicado: (2014)

Targeting Mcl-1 for Radiosensitization of Pancreatic Cancers()()
por: Wei, Dongping, et al.
Publicado: (2015)

Concurrent Inhibition of Akt and ERK Using TIC-10 Can Overcome Venetoclax Resistance in Mantle Cell Lymphoma
por: Granau, Agnete Marie, et al.
Publicado: (2023)

TRES, a validated three-factor comorbidity score, is associated with survival in older patients with mantle cell lymphoma
por: Gordon, Max J., et al.
Publicado: (2023)

Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma: the Fondazione Italiana Linfomi MCL0208 trial
por: Ferrero, Simone, et al.
Publicado: (2023)

Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study
por: Wang, Michael, et al.
Publicado: (2021)

Polatuzumab‐bendamustine‐rituximab as bridge to CD19‐directed CAR T cells in mantle cell lymphoma refractory to ibrutinib and venetoclax
por: Perriello, Vincenzo Maria, et al.
Publicado: (2023)

Pirtobrutinib and venetoclax combination overcomes resistance to targeted and chimeric antigen receptor T-cell therapy in aggressive mantle cell lymphoma
por: Liu, Yang, et al.
Publicado: (2022)

The Therapeutic Synergy of Selinexor and Venetoclax in Mantle Cell Lymphoma Through Induction of DNA Damage and Perturbation of the DNA Damage Response
por: Yuan, Sheng, et al.
Publicado: (2023)

Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study
por: Zinzani, P. L., et al.
Publicado: (2013)

COVID-19 infection outcomes in patients receiving CD20 targeting T-cell engaging bispecific antibodies for B-cell non-Hodgkin lymphoma
por: Nachar, Victoria R., et al.
Publicado: (2023)

Protein Kinase CK2 represents a new target to boost Ibrutinib and Venetoclax induced cytotoxicity in mantle cell lymphoma
por: Manni, Sabrina, et al.
Publicado: (2022)

A sumoylation program is essential for maintaining the mitotic fidelity in proliferating mantle cell lymphoma cells
por: Hanel, Walter, et al.
Publicado: (2022)

Prospective subgroup analyses of the randomized MCL‐002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma
por: Arcaini, Luca, et al.
Publicado: (2017)

The Feasibility of Virtual Toxicity Assessments in Lymphoma Patients Receiving Immunochemotherapy
por: Runge, John S., et al.
Publicado: (2020)

ASTCT, CIBMTR and EBMT Clinical Practice recommendations for transplant and cellular therapies in mantle cell lymphoma.
por: Munshi, Pashna N., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_le9vsfc6jhpdjbfl42mo2l3jjj